Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of thalidomide- and lenalidomide-based combinations in newly diagnosed multiple myeloma
ISRCTN49407852Phase 3Completed
- Sponsor
- University of Leeds
- Start
- May 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide, lenalidomide, carfilzomib, bortezomib, cyclophosphamide and 2 more in multiple myeloma (MM) (8 arms), sponsored by University of Leeds. Primary endpoints: Overall survival and Progression-free survival. Started May 2010; status: completed.
02
Drugs
thalidomidelenalidomidecarfilzomibbortezomibcyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN49407852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49407852.